Ne
Non verificato

Neurogene Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza
28/04/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
1.00
20/04/2026
Mercato del lavoro
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
1.00
08/04/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
24/03/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
1.00
11/03/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Scienza
Farmaceutica
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
1.00
03/03/2026
Finanza
Biotecnologia
Farmaceutica
Salute
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
26/02/2026
Industria
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
1.00
05/02/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Scienza
Farmaceutica
Neurogene to Participate in Upcoming Investor Conferences
1.00
04/02/2026
Biotecnologia
Farmaceutica
Salute
Finanza
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1.00
12/01/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Web e Social Network
Eventi
Industria
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0